Recurrent vulvovaginal candidiasis with <i>Candida glabrata</i> - a management conundrum.

High rates of azole-resistance and limited availability of pharmacological agents within the UK can make recurrent vulvovaginal candidiasis (RVVC) with <i>Candida glabrata</i> a challenging infection to treat. In this report, we describe our experience in managing <i>C. glabrata</i> RVVC and present the case of a patient with poor response to therapy and a protracted treatment course, spanning almost 4 years. We also highlight the need for evidence-based management protocols that consider the national availability of alternative treatments.